With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from ...

Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared to placebo in Phase 3 trials Enlicitide had a favorable ...

New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

LISBON, Portugal — Using RNA interference to inhibit proprotein convertase subtilisin kexin type 9 (PCSK9) synthesis lowers levels of atherogenic lipoproteins across the board, new results suggest. At ...

An expert discusses how nonstatin therapies serve as essential tools when patients can’t tolerate statins or need additional ...

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant and clinically meaningful cuts in low ...

Findings showed the trial met the primary endpoint, with enlicitide demonstrating a statistically significantly meaningful reduction in LDL-C compared with placebo. Topline data were announced from a ...

Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study Enlicitide is the ...